chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pt. got her 2 month vaccines and was noted to have abnormal movements bilaterally.   She was taken to the hospital and monitored for 1 day and was discharged home as the movements stopped.
3 hours post vax, the pt developed hives and a rash across her shoulders posteriorly, that self resolved. The pt reportedly recovered from this experience. No additional info was provided from correspondence returned on 07/25/2000. No further info is anticipated, this case is closed.
Patient and husband received IM influenza vaccination at clinic. After leaving, within an hour of injection, they drove a short distance to a family member's home; patient was unsteady walking and collapsed, unresponsive, outside. Husband also was found unresponsive in car. Emergency services personnel responded: patient's blood glucose level was documented at 11 mg/dl. Treated with 3 ampoules of 50% dextrose in the field at 3:15PM, followed by D10 in ER. Patient blood glucose normalized and patient was admitted to an outside hospital (accompanied husband, who required a higher level of care) about 7pm. Husband also extremely hypoglycemic: his report is separate. Do not have records from hospital.
Pt was TBR (new patient) no hx of vaccines per mom; no medical care. Child had all immunizations noted below at visit. Had a rash viral in etiology that comes and goes per mom. Child was brought to hospital 10/2/2011 with abscess to (R) thigh. I&D consult/surgery consult mode - child has fever and is on antibx.
Patient had an injection site reaction in left arm. Presented with rash/redness covering upper left arm.
Report A0371830A describes bloody diarrhea in a 45 year old male who received hep A vaccine inactivated. There was no relevant medical history, concurrent conditions, or concurrent medications specified. The subject reported alcohol use of two drinks per week and denied tobacco use. The subject had no adverse experiences following receipt of prior immunizations. On 6/14/02, the subject received his first injection of Havrix. One hour post immunization, the subject experienced "bloody" diarrhea, stomach pain, joint pain, and fever of 101 deg F. The vaccinee was sent to the ER for further evaluation. Follow up info received on 7/16/02 from the reporting nurse indicated that the events of bloody diarrhea, stomach pain and fever resolved on 6/21/02, while the event of joint pain subsequently resolved on 6/28/02. It was noted that the immunization series was discontinued. The reporting nurse considered the events to be possibly related to Havrix immunization.
VERY SORE ARM/PAIN AT INJECTION AREA ALONG WITH ITCHINESS, REDNESS, SWELLING AND HEAT IMMEDICATELY AFTER THE INJECTION WHICH LASTED FOR 4 DAYS.  I EXPERIENCED CHILLS, SORE THROAT AND FATIGUE THE FOLLOWIND DAY (AROUND 18 HOURS LATER) WHICH LASTED FOR 28 HOURS.  AFTER 27 HOURS, I ALSO EXPERIENCED A FEVER OF 100.2 AND SLIGHT BODY ACHES AS WELL AS ALL OF THE ABOVE MENTIONED WHICH LASTED AROUND 12 HOURS.
11:25 IZ given (R) deltoid IM. 11:30 Fainted - administered ammonia inhalant - no response. BP 110/70 P 68 R 24 stable VS pale, lying down - conscious. 11:42 BP 106/62 P 72 R 28 stomach ache; no vomiting, responsive. 11:48 BP 110/70 P 68 R 24. 12:00 BP 108/70 P 66 R 22 - sitting position, drinking juice. 12:20 BP 110/70, P 72 R 20 - says chest hurts - 911 called & to ER consulted with MD. 8/8/11 conversation with his mother & she said ER said he might have had simple fainting (vasovagal syncope) & fear of needles. No further treatment.
Shortness of breath the day of second vaccine with ambulation increased over the week. Went into hospital thinking it was lingering covid vaccine and was diagnosed with LAD Heart attack with stent - EF is now 25% and requiring an AICD - he exercised multiple times a week, including running prior to getting the second vaccine
Narrative: Patient was not previously COVID-19 positive and did not have any predisposing factors(PMH, allergies, etc) for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. PMH significant for adenocarcinoma of pancreas, sleep apnea, malignant neoplasm of pancreas, aortic stenosis, diabetes, neuropathy, vitamin d deficiency, gout, angina, dyslipidemia, CAD. Pt was under the care of Hospice for end stage pancreatic adenocarcinoma. No information regarding death available.
7 days after my daughter first Pfizer shot she began to experience cognitive decline, hard to wake up, had sharp pain in back of her neck and head experienced weakness in her limps lost feeling in thighs, knees and legs. Her ability to walk was limited she said her legs felt like jelly. Today she has improved but suffers with memory fog, no feeling in legs and stability issues.
Pt. inadvertently given Pfizer monovalent formulation instead of bivalent. at community event.  Pt. informed.
lightheaded; hands started crumping; fever; arm  hurt; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (arm  hurt), DIZZINESS (lightheaded), MUSCLE SPASMS (hands started crumping) and PYREXIA (fever) in a 24-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Apr-2021, the patient experienced PAIN IN EXTREMITY (arm  hurt) and PYREXIA (fever). On 13-Apr-2021, the patient experienced DIZZINESS (lightheaded) and MUSCLE SPASMS (hands started crumping). The patient was treated with IBUPROFEN at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (arm  hurt) and PYREXIA (fever) had resolved and DIZZINESS (lightheaded) and MUSCLE SPASMS (hands started crumping) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Po concomitant medications were reported.
This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE CELLULITIS (Cellulitis at injection site; red, swollen, warm, and painful) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     The patient's past medical history included Gastritis. Concomitant products included SUCRALFATE (CARAFATE), AMOXICILLIN TRIHYDRATE, CLARITHROMYCIN, ESOMEPRAZOLE MAGNESIUM (NEXIUM 1-2-3) and FAMOTIDINE for Gastritis.    On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Jan-2021, the patient experienced VACCINATION SITE CELLULITIS (Cellulitis at injection site; red, swollen, warm, and painful). At the time of the report, VACCINATION SITE CELLULITIS (Cellulitis at injection site; red, swollen, warm, and painful) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Patient reported sudden-onset of violent coughing, generalized body aches, chills, fever, runny nose, swollen eyes with greenish discharge at approximately 9 PM on 2/5/14, approx 5 hrs after flu vaccine administration.
Pt c/o headache x 2 days and CP with breathing x 2days. Patient referred to cardiology.  9/29/09 Cardiology consultation records received DOS 9/14/09 to 9/16/09. Includes orthopedic imaging studies from 2/5/09 and 6/16/09. Assessment: Aortic Regurgitation. Patient presents with chest pain.
This is a spontaneous report received from a contactable reporter(s) (other HCP). A male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunization. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: SOMNOLENCE (non-serious), outcome "recovered" (reported as no more than 3 days), described as "sleepiness". No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Linked Report(s): US-PFIZER INC-202101333902 same reporter/drug/different patient; US-PFIZER INC-202101333934 same reporter/drug/different patient.
Patient felt  weakness, Headache and nausea.  Patient was asked to stay hydrated, take rest, tylenol for headache/body ache, meclizine for nausea.  Patient has been instructed to go to see a dr. if symptomps worsens.
swelling, like a bump, redness and itchiness at the injection site; swelling, like a bump, redness and itchiness at the injection site; swelling, like a bump, redness and itchiness at the injection site; as the vaccine provider remove the needle from the arm, they felt some liquid running down their arm; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE EXTRAVASATION (as the vaccine provider remove the needle from the arm, they felt some liquid running down their arm), INJECTION SITE PRURITUS (swelling, like a bump, redness and itchiness at the injection site), INJECTION SITE SWELLING (swelling, like a bump, redness and itchiness at the injection site) and INJECTION SITE ERYTHEMA (swelling, like a bump, redness and itchiness at the injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012M20A) for COVID-19 vaccination.     Concomitant products included type 1 diabetes oral medication and hypothyroidism oral medication for an unknown indication.    On 02-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Feb-2021, the patient experienced INJECTION SITE EXTRAVASATION (as the vaccine provider remove the needle from the arm, they felt some liquid running down their arm). On an unknown date, the patient experienced INJECTION SITE PRURITUS (swelling, like a bump, redness and itchiness at the injection site), INJECTION SITE SWELLING (swelling, like a bump, redness and itchiness at the injection site) and INJECTION SITE ERYTHEMA (swelling, like a bump, redness and itchiness at the injection site). On 02-Feb-2021, INJECTION SITE EXTRAVASATION (as the vaccine provider remove the needle from the arm, they felt some liquid running down their arm) had resolved. At the time of the report, INJECTION SITE PRURITUS (swelling, like a bump, redness and itchiness at the injection site), INJECTION SITE SWELLING (swelling, like a bump, redness and itchiness at the injection site) and INJECTION SITE ERYTHEMA (swelling, like a bump, redness and itchiness at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Itchy; Warm; Fever; Nausea; Headache; Chills; Sore arm around previous TBC vaccine; Swelling around previous TBC vaccine/swollen arm reappear; Redness around previous TBC vaccine/redness on arm reappear/ The scar of BCG turned red; Night sweat/night sweat reappear; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm around previous TBC vaccine), PERIPHERAL SWELLING (Swelling around previous TBC vaccine/swollen arm reappear), ERYTHEMA (Redness around previous TBC vaccine/redness on arm reappear/ The scar of BCG turned red), NIGHT SWEATS (Night sweat/night sweat reappear) and PRURITUS (Itchy) in a 33-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 021B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Previously administered products included for Product used for unknown indication: TBC (Received TBC vaccine 30 years ago.) in 1991 and BCG. Past adverse reactions to the above products included No adverse event with BCG and TBC. Concurrent medical conditions included Asthma (Asthma medication, inhaler.).    On 30-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Mar-2021, the patient experienced PAIN IN EXTREMITY (Sore arm around previous TBC vaccine), PERIPHERAL SWELLING (Swelling around previous TBC vaccine/swollen arm reappear), ERYTHEMA (Redness around previous TBC vaccine/redness on arm reappear/ The scar of BCG turned red), NIGHT SWEATS (Night sweat/night sweat reappear), PYREXIA (Fever), NAUSEA (Nausea), HEADACHE (Headache) and CHILLS (Chills). On 09-Apr-2021, the patient experienced PRURITUS (Itchy) and FEELING HOT (Warm). On 02-Apr-2021, PYREXIA (Fever), NAUSEA (Nausea) and HEADACHE (Headache) had resolved. On 04-Apr-2021, PAIN IN EXTREMITY (Sore arm around previous TBC vaccine) had resolved. On 11-Apr-2021, NIGHT SWEATS (Night sweat/night sweat reappear) had resolved. At the time of the report, PERIPHERAL SWELLING (Swelling around previous TBC vaccine/swollen arm reappear) and FEELING HOT (Warm) had not resolved, ERYTHEMA (Redness around previous TBC vaccine/redness on arm reappear/ The scar of BCG turned red) and PRURITUS (Itchy) had resolved and CHILLS (Chills) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 30-Mar-2021, Heart rate: increased (High) increased.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications include asthma medication, inhaler.  Treatment for the event included paracetamol.   This case was linked to MOD-2021-128549 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 13-Apr-2021: Non significant follow up appended. On 13-May-2021: Case created for 2nd dose of vaccine. Updated patient's contact details. The outcome of the event "Redness" changed (from Not resolved to resolved).
This spontaneous report as received from a Registered Nurse, refers to patient of unknown age and gender. Medical history and concurrent conditions were not reported. The reporting nurse stated that a celebrity noted a "change" in her child after her child was vaccinated with a dose of M-M-R II (dose, route, lot number and expiration date were not provided). No concomitant medication was reported. This is one of several reports from the same reporter. Additional information has been requested.
Narrative:  COVID infection following COVID vaccine series 02/02, Pfizer, dose #1 02/23, Pfizer, dose #2 07/28 pt cc: cough, diarrhea, headache, rhinorrhea exposure: +COVID room mate & went to an event with grand-daughter 08/03 COVID swab, result: detected 08/04 pt report symptoms improving 08/06 pt cc: none clinically resolved
WBC /After the 3rd booster in Oct2022, it was 2.3. It is now 1.7.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID. The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), in Oct2022 as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, SINGLE), for COVID-19 immunization; Bnt162b2 (DOSE 2, SINGLE), administration date: 2021, for COVID-19 immunization, reaction(s): "WBC was 3.4 and has been dropping since". The following information was reported: WHITE BLOOD CELL COUNT DECREASED (medically significant) with onset Oct2022, outcome "not recovered", described as "WBC /After the 3rd booster in Oct2022, it was 2.3. It is now 1.7.". The patient underwent the following laboratory tests and procedures: White blood cell count: (unspecified date) 7.8, notes: Before vaccination; (2021) 3.4, notes: After second shot; (Oct2022) 2.3; (2023) 1.7. Patient was working with a rheumatologist and hematologist, but they can't figure it out.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-PV202300037577 same patient, different vaccine dose, different event;
Needle used was actually a shorter subcutaneous needle although it was given IM; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG TECHNIQUE IN DEVICE USAGE PROCESS (Needle used was actually a shorter subcutaneous needle although it was given IM) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced WRONG TECHNIQUE IN DEVICE USAGE PROCESS (Needle used was actually a shorter subcutaneous needle although it was given IM). At the time of the report, WRONG TECHNIQUE IN DEVICE USAGE PROCESS (Needle used was actually a shorter subcutaneous needle although it was given IM) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The  concomitant medications on use were not provided. No treatment information was provided.
Onset at 5 hours post injection, with headache (which lasted for 2-3 days), chills, and vomiting (3 times), both sxs lasted about 3-4 hours.
pt recv vax 26MAR98 & devel fever of 102.5 & irritability;6 days post vax 1APR98 pt devel conjunctivitis;
Bexsero administered instead of Trumemba; This case was reported by a physician via call center representative and described the occurrence of interchange of vaccine products in a 17-year-old female patient who received Men B NVS (Bexsero) (batch number KL472, expiry date 30th September 2024) for prophylaxis.   Co-suspect products included meningococcal B recom vaccine + aloh + omv pre-filled syringe device (Bexsero Pre-Filled Syringe Device) injection syringe for prophylaxis and MENINGOCOCCAL B VACCINE (TRUMENBA) for prophylaxis.   On 28th December 2022, the patient received Bexsero and Bexsero Pre-Filled Syringe Device. On 17th January 2022, the patient received the 1st dose of TRUMENBA. On 28th December 2022, unknown after receiving Bexsero and Bexsero Pre-Filled Syringe Device, the patient experienced interchange of vaccine products. On an unknown date, the outcome of the interchange of vaccine products was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 28-DEC-2022 Reporter's Comments: The physician stated that patient came in for second dose of Trumenba but the staff administered a dose of Bexsero instead of Trumenba.   The vaccine administration facility was the same as primary reporter. The reporter gave permission for follow-up. Additional Supportive Information: The patient received Bexsero instead of Trumenba, which led to interchange of vaccine products.
Swelling, pain, some bruising in site left deltoid area. Redness, size of orange. Prednisone ordered by Dr.
Cold sweats mostly at night sometimes during the day, body aches, joint pain, burning sensation in stomach mostly at night.  Symptoms generally come in waves and are at times more tolerable than others.
Varicella vaccine given 1/23/03. 3 days later, hard lump noted in L leg. This became increasingly redder over next week. Plan warm soaks.
PT HAD RECIEVED THE PFIZER VACCINE ON 6/29/21 BEFORE BEING ARRESTED.PT IN ERROR WAS GIVEN MODERNA AS THE SENCOND DOSE ON 8/17/21
The right side of my face was paralize i could not talk or chew food or hear to well my right ear....for three months was very critical it gotten better with time but i still not one hundred percent
Adacel given 3/31/06, pt became pruritic next day. 4/18 developed severe urticaria, chest pain, wheezing and facial swelling, other agents may be involved. 4/25/06 Received medical records from PCP which reveal patient developed hives on 4/16/06.  Tx w/adrenaline, Zyrtec & Medrol dose pack w/worsening of s/s to include nausea, facial/lip/tongue swelling.  Admitted for overnight hospital stay w/dx suspected Diamox reaction althouth had taken Diamox 4-5 times w/no prior reaction (takes 1 wk/mo for headaches preceeding her menstrual cycle).   PMH: MS (tx w/interferon).
Severe muscle pain and achiness, chills, temperature of 99.5F. Awakened from sleep approximately 04:30 on 7/21/05. Was given Motrin by parent. Shortness of breath started and went to ER. ER gave steroids, Benadryl and IV per mother.
Pt complained of low back pain, beginning 3 hours, post vax. No fever, rashes, nausea or vomiting or any other myalgias. No radiation of pain, no bowel or bladder or other weakness.
Rash on abdomen approximately 2x4 inches with slight itching that lasted about 3 hours without requiring any treatment.
pt had vax in early afternoon; @ approx 5PM started screaming cont for most of evening & into the night unconsolably; was fine the next day;
24 hours after being vaccinated patient experienced intense itching all over scalp.  48 hours after vaccination she developed a small sore at the base of her hairline which scabbed over the following day.   She treated herself with diphenhydramine for 2 days until the itching resolved.
Dose 1 on 12/15- Sore arm for three days after vaccination. Swelling also was present on the deltoid. Upon resolution a large bruise showed up.    Dose 2 on 01/05- Sore arm near vaccination site at 12 hours. At 15 hours out woke up in middle of the night with diffuse body aches and chills. These progressively worsened. Fatigue also present in the morning with very mild fever.  Developed nausea the next day as well. At 36 hours out body aches were improving but a headache developed at ~ 30 hours out. Next morning 2 days out the only thing thing that persisted was fatigue. This was gone another 12 hours later.  No persistent symptoms.
Information has been received from a health professional concerning an unknown number of female patients who were vaccinated intramuscularly with Gardasil vaccine. Subsequently, the patients experienced injection site pain. The patients are in the office for the administration and comment on the pain after administration. The patients are immigrants and received multiple vaccinations in one visit and they comment that the Gardasil injection is more painful than the others. The nurse says she tells patients before hand that the Gardasil will hurt more than the other vaccine, so she is not sure if that is contributing to the complaints. Additional information has been requested.
Patient was waiting in a chair after the vaccine and bent over to pick up a phone off of the ground. He got lightheaded and passed out as he was bending over. The patient hit his head and briefly passed out. We got him to the ground slowly and provided him with an ice pack and bottle of water. He was breathing quickly and shallowly for about 30 seconds but returned to normal shortly after.
26 patients were given a booster for COVID that was not Pfizer/Moderna Bivalent booster. We did not have vaccines available to administer until 10/12/22.
On day of vaccine I became a little flush 30 minutes after vaccination. Next day, arm hurt. Otherwise I felt fine. 5 days after receiving the vaccination I noticed I was dizzy when standing up in the AM. Late AM I developed a headache  which got more severe in the afternoon through the evening and was accompanied by nausea, chills, briefly high heart rate (199), fatigue,  and  the dizziness. Took 2 Tylenol in the evening . 2 hrs later symptoms improved dramatically. Felt a little unsteady today.